FDA will convene the Pharmacy Compounding Advisory Committee (PCAC) on July 23-24, 2026, to discuss seven peptides for potential inclusion on the 503A bulks list. An additional five peptides will be ...

FormBlends, a telehealth platform focused on medically supervised GLP-1 therapy and peptide research, today released its 2026 ...

With Health Secretary Robert F. Kennedy Jr. declaring himself “a big fan of peptides,” the FDA has arranged an advisory ...

You’ve probably seen compounding making headlines recently, and not for the right reasons. From so-called “personalized” GLP-1s flooding the market to telehealth startups touting hormone “rebalancing” ...

Every investor has heard this quote at least once in their career: “Compound interest is the eighth wonder of the world. He who understands it earns it. He who doesn’t pays it," is a quote often ...

In March, Pharmaceutical Executive reported on Eli Lilly’s efforts to push back against the availability of compounded GLP-1 ...

Since 2022, four GLP-1 drugs, including those indicated for weight loss, have been on FDA’s drug shortage list due to extraordinarily high patient demand. The shortage has, in turn, resulted in ...

Please provide your email address to receive an email when new articles are posted on . As of the end of October, 28 deaths resulting from the use of poorly prepared compounded medications by a ...

The S&P 500 index has yielded a 220% return in the last 10 years. Peter Mallouk, the CEO of Creative Planning Inc., highlights this data and recalls veteran investor Charlie Munger‘s insights on the ...

Pharmaceutical companies in Europe are blocking the sale of drugs used for lethal injection in the U.S. That has states that use the drugs turning to compounding pharmacies to create them. David ...